Super Sessions : Biotech’s Contribution to Innovation: Current and Future Drivers of Success

jun 4, 2019: 2:30 p.m. - 3:45 p.m.
Room 113ABC

Sponsored by: IQVIA Biotech

With their involvement in over 70% of the clinical pipeline %u2014 whether they partner, license or commercialize on their own %u2013 biotech companies continue to be the driving force behind innovation in drug development. This session will explore the current state of innovation within biotech companies and examine what is on the horizon for these companies. What are the critical success factors that will help them be best prepared to sustain their contribution to innovation and improvement in human health? Findings from a new IQVIA Institute research report will be presented followed by a panel discussion of the implications from the perspective of biotech, large pharma and investors. The report will provide a comprehensive landscape of the current state of biotech activity, including R&D, commercialization of new molecules, and strategic transactions. It will assess the potential impact of environmental factors including financing, technology, big data and machine learning, regulations, demand for medicines and payer actions. The report will also lay out ways in which data and analytics, technology and flexible business models can be applied to ensure the future success of biotech companies as an integral part of the innovation-based human health ecosystem.

Speakers

Murray Aitken
Executive Director

Stacy Lindley
Vice President and Hea...

William Hait
Global Head, Johnson &...

Arthur Pappas
Managing Director

Tara Rheault
Vice President, R&D an...

Anne Whitaker
Chief Executive Office...